263 related articles for article (PubMed ID: 29891542)
1. Urine Cytokine and Chemokine Levels Predict Urinary Tract Infection Severity Independent of Uropathogen, Urine Bacterial Burden, Host Genetics, and Host Age.
Armbruster CE; Smith SN; Mody L; Mobley HLT
Infect Immun; 2018 Sep; 86(9):. PubMed ID: 29891542
[TBL] [Abstract][Full Text] [Related]
2. Analysis of inflammatory cytokine expression in the urinary tract of BALB/c mice infected with Proteus (P.) mirabilis and enteroaggregative Escherichia (E.) coli (EAEC) strains.
Melendez-Avalos A; Sainz-Espuñes T; Castrillón-Rivera LE; Mendoza-Pérez F; Palma-Ramos A; Castañeda-Sánchez JI; Drago-Serrano EM
Folia Microbiol (Praha); 2020 Feb; 65(1):133-142. PubMed ID: 31104302
[TBL] [Abstract][Full Text] [Related]
3. d-Serine Degradation by Proteus mirabilis Contributes to Fitness during Single-Species and Polymicrobial Catheter-Associated Urinary Tract Infection.
Brauer AL; White AN; Learman BS; Johnson AO; Armbruster CE
mSphere; 2019 Feb; 4(1):. PubMed ID: 30814316
[No Abstract] [Full Text] [Related]
4. The Pathogenic Potential of Proteus mirabilis Is Enhanced by Other Uropathogens during Polymicrobial Urinary Tract Infection.
Armbruster CE; Smith SN; Johnson AO; DeOrnellas V; Eaton KA; Yep A; Mody L; Wu W; Mobley HLT
Infect Immun; 2017 Feb; 85(2):. PubMed ID: 27895127
[TBL] [Abstract][Full Text] [Related]
5. In vivo phase variation of MR/P fimbrial gene expression in Proteus mirabilis infecting the urinary tract.
Zhao H; Li X; Johnson DE; Blomfield I; Mobley HL
Mol Microbiol; 1997 Mar; 23(5):1009-19. PubMed ID: 9076737
[TBL] [Abstract][Full Text] [Related]
6. Proteus mirabilis urinary tract infection and bacteremia: risk factors, clinical presentation, and outcomes.
Chen CY; Chen YH; Lu PL; Lin WR; Chen TC; Lin CY
J Microbiol Immunol Infect; 2012 Jun; 45(3):228-36. PubMed ID: 22572004
[TBL] [Abstract][Full Text] [Related]
7. Early Increased Urinary IL-2 and IL-10 Levels Were Associated With Development of Chronic UTI in a Murine Model.
Zhu K; Hill WG; Li F; Shi B; Chai TC
Urology; 2020 Jul; 141():188.e1-188.e6. PubMed ID: 32201154
[TBL] [Abstract][Full Text] [Related]
8. The type III secretion system of Proteus mirabilis HI4320 does not contribute to virulence in the mouse model of ascending urinary tract infection.
Pearson MM; Mobley HLT
J Med Microbiol; 2007 Oct; 56(Pt 10):1277-1283. PubMed ID: 17893161
[TBL] [Abstract][Full Text] [Related]
9. Comparative Genomics of Antibiotic-Resistant Uropathogens Implicates Three Routes for Recurrence of Urinary Tract Infections.
Thänert R; Reske KA; Hink T; Wallace MA; Wang B; Schwartz DJ; Seiler S; Cass C; Burnham CA; Dubberke ER; Kwon JH; Dantas G
mBio; 2019 Aug; 10(4):. PubMed ID: 31455657
[TBL] [Abstract][Full Text] [Related]
10. Catalase Activity is Critical for Proteus mirabilis Biofilm Development, Extracellular Polymeric Substance Composition, and Dissemination during Catheter-Associated Urinary Tract Infection.
White AN; Learman BS; Brauer AL; Armbruster CE
Infect Immun; 2021 Sep; 89(10):e0017721. PubMed ID: 34280035
[TBL] [Abstract][Full Text] [Related]
11. Uropathogens and host characteristics.
Tabibian JH; Gornbein J; Heidari A; Dien SL; Lau VH; Chahal P; Churchill BM; Haake DA
J Clin Microbiol; 2008 Dec; 46(12):3980-6. PubMed ID: 18842936
[TBL] [Abstract][Full Text] [Related]
12. Identification of protease and rpoN-associated genes of uropathogenic Proteus mirabilis by negative selection in a mouse model of ascending urinary tract infection.
Zhao H; Li X; Johnson DE; Mobley HLT
Microbiology (Reading); 1999 Jan; 145 ( Pt 1)():185-195. PubMed ID: 10206698
[TBL] [Abstract][Full Text] [Related]
13. Bacterial virulence phenotypes of
Schreiber HL; Conover MS; Chou WC; Hibbing ME; Manson AL; Dodson KW; Hannan TJ; Roberts PL; Stapleton AE; Hooton TM; Livny J; Earl AM; Hultgren SJ
Sci Transl Med; 2017 Mar; 9(382):. PubMed ID: 28330863
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection.
Alamuri P; Eaton KA; Himpsl SD; Smith SN; Mobley HL
Infect Immun; 2009 Feb; 77(2):632-41. PubMed ID: 19029299
[TBL] [Abstract][Full Text] [Related]
15. Preferential use of central metabolism in vivo reveals a nutritional basis for polymicrobial infection.
Alteri CJ; Himpsl SD; Mobley HL
PLoS Pathog; 2015 Jan; 11(1):e1004601. PubMed ID: 25568946
[TBL] [Abstract][Full Text] [Related]
16. The high-affinity phosphate transporter Pst is a virulence factor for Proteus mirabilis during complicated urinary tract infection.
Jacobsen SM; Lane MC; Harro JM; Shirtliff ME; Mobley HL
FEMS Immunol Med Microbiol; 2008 Mar; 52(2):180-93. PubMed ID: 18194341
[TBL] [Abstract][Full Text] [Related]
17. Effects of the administration of cholera toxin as a mucosal adjuvant on the immune and protective response induced by Proteus mirabilis MrpA fimbrial protein in the urinary tract.
Scavone P; Rial A; Umpierrez A; Chabalgoity A; Zunino P
Microbiol Immunol; 2009 Apr; 53(4):233-40. PubMed ID: 19714860
[TBL] [Abstract][Full Text] [Related]
18. Construction and evaluation of the immune protection of a recombinant divalent protein composed of the MrpA from MR/P fimbriae and flagellin of Proteus mirabilis strain against urinary tract infection.
Habibi M; Asadi Karam MR; Bouzari S
Microb Pathog; 2018 Apr; 117():348-355. PubMed ID: 29452195
[TBL] [Abstract][Full Text] [Related]
19. Modulation of host innate immune response in the bladder by uropathogenic Escherichia coli.
Billips BK; Forrestal SG; Rycyk MT; Johnson JR; Klumpp DJ; Schaeffer AJ
Infect Immun; 2007 Nov; 75(11):5353-60. PubMed ID: 17724068
[TBL] [Abstract][Full Text] [Related]
20. Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis.
Habibi M; Asadi Karam MR; Bouzari S
APMIS; 2016 Jun; 124(6):444-52. PubMed ID: 26918627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
